Arthritis Innovation Corporation (AIC) is a clinical-stage pharmaceutical company addressing unmet needs in orthopedic surgery and arthritis management.   A private company founded in 2013, AIC leverages a world-class product development team located in Toronto, Canada and Denver, Colorado, and a proprietary polymer drug delivery system (BEPO®) formulated with previously marketed drugs. 

AIC's first drug in clinical development, called F14, brings sustained, local delivery of the well-known NSAID, celecoxib (marketed as Celebrex) for the management of pain and inflammation after total knee replacement (TKR) surgery, as an alternative to narcotics or oral NSAIDs.  In November of 2022, AIC commenced enrolment into their US multicenter Phase 3 trial studying F14 efficacy.                                                                                                         

Completed Phase 2 Study: Clinicaltrials.gov: NCT03541655.   For more information, click HERE.

Ongoing Phase 3 Study:  Clinicaltrials.gov: NCT05603832.  For more information, click HERE.